Literature DB >> 6733702

Long persistence of doxorubicin in human skin after extravasation.

P Sonneveld, H A Wassenaar, K Nooter.   

Abstract

Extravasation of doxorubicin (DXR) from a dorsal hand vein is described. At 28 days following this event, high dermal concentrations of DXR were still present, not only at the injection site (1.7 X 10(-6) M X g-1) but also at a distance of 5 cm (0.4 X 10(-6) m X g-1. This long persistence of DXR in the skin necessitates ample excision of the skin following severe extravasation of the drug.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6733702

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  7 in total

1.  Vacuum-Sealing as a Treatment Option for Severe Anthracycline Extravasation in a Breast Cancer Patient.

Authors:  Kerstin Rhiem; André T Nemat; Rita K Schmutzler; Matthias Krick; Peter Mallmann; Mathias Warm
Journal:  Breast Care (Basel)       Date:  2008-10-17       Impact factor: 2.860

Review 2.  Dexrazoxane for the prevention of cardiac toxicity and treatment of extravasation injury from the anthracycline antibiotics.

Authors:  James H Doroshow
Journal:  Curr Pharm Biotechnol       Date:  2012-08       Impact factor: 2.837

Review 3.  Prevention and management of extravasation of cytotoxic drugs.

Authors:  G Bertelli
Journal:  Drug Saf       Date:  1995-04       Impact factor: 5.606

Review 4.  Extravasation of antineoplastic agents: prevention and treatments.

Authors:  Rita Boschi; Elena Rostagno
Journal:  Pediatr Rep       Date:  2012-08-01

5.  A sarcoma at the site of previous extravasation of adriamycin.

Authors:  Joris Ceulemans; Ivo De Wever; Raf Sciot; Maria Debiec-Rychter; Allan T van Oosterom
Journal:  Sarcoma       Date:  2002

Review 6.  Dexrazoxane for the treatment of chemotherapy-related side effects.

Authors:  Seppo W Langer
Journal:  Cancer Manag Res       Date:  2014-09-15       Impact factor: 3.989

7.  Toxicological aspects of a novel 9-aminoanthracycline, SM-5887.

Authors:  S Morisada; Y Yanagi; Y Kashiwazaki; M Fukui
Journal:  Jpn J Cancer Res       Date:  1989-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.